Scangos "working" on reuniting Biogen in Cambridge; Indian billionaire's 50-cent vax beats a jab from GSK;

@FierceBiotech: Cancer drug collaborations are hot. Story | Follow @FierceBiotech

@JohnCFierce: Interesting Xconomy piece on Somnus, but de-risked sleep meds relying on new delivery tech just looks weak to me. News | Follow @JohnCFierce

> George Scangos, the new CEO at Biogen Idec, has made no secret of his desire to reunite his headquarters team with its Cambridge R&D ops. In an interview with Xconomy, he says that "We're working on it. We'll see if it's practical." Story

> A 50-cent vaccine developed at the Serum Institute of India-head by billionaire Cyrus Poonawalla--worked better than a standard jab from GlaxoSmithKline at protecting people from meningitis. Story

> Cubist Pharmaceuticals says it has gathered positive top-line results from the recently completed Phase II studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. Report

> Glasgow-based Lamellar Biomedical says that its lead drug for cystic fibrosis has won orphan drug status from the European Commission. Release

Pharma News

@FiercePharma: Sanofi moves deeper into Genzyme operations. Item | Follow @FiercePharma

> Are drugmakers suffering from complexity? Article

> Analysts eye survivors of $250B patent cliff. Article

> Restaurateurs join call to lift MA gift ban. Story

> J&J to exit stents, cut 1,000 jobs. Report

> FDA highlights cancer risk with Takeda's Actos. News

Vaccines News

> Immatics starts late-stage cancer vaccine study. News 

> Type I diabetes nasal vaccine on the horizon. Item 

> GSK boosts China presence with flu vaccine buyout. Story

> BiondVax releases promising Ph2 universal flu vax results. Article

> Cheap meningitis vax beats out GSK's version. Story

> GSK, Arecor form vaccine stabilization pact. Article

Manufacturing News 

> Expert: FDA inadvertantly causing drug shortages. News

> APP expansion could help fight against drug shortages. Item 

> Dr. Reddy's tarnished by FDA warning, fire probe. Story 

> GSK deals to boost vax stability, fight flu in Asia. Report 

> Fidelity mutual fund rides big pharma profits. Item

And Finally... In the back-and-forth argument over the potential link between cell phones and brain cancer, a new study covered by Reuters Health says that most tumors found in the brain are not within the radius of the radiation mobile phones emit. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.